WO2020139991A1 - Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer - Google Patents

Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer Download PDF

Info

Publication number
WO2020139991A1
WO2020139991A1 PCT/US2019/068652 US2019068652W WO2020139991A1 WO 2020139991 A1 WO2020139991 A1 WO 2020139991A1 US 2019068652 W US2019068652 W US 2019068652W WO 2020139991 A1 WO2020139991 A1 WO 2020139991A1
Authority
WO
WIPO (PCT)
Prior art keywords
carcinoma
cancer
alkyl
optionally substituted
compound according
Prior art date
Application number
PCT/US2019/068652
Other languages
English (en)
French (fr)
Inventor
Zenon D. Konteatis
Mingzong Li
Samuel K. REZNIK
Zhihua Sui
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PE2021001086A priority Critical patent/PE20212090A1/es
Priority to MA54608A priority patent/MA54608B1/fr
Priority to MDE20211082T priority patent/MD3902803T2/ro
Priority to FIEP19845796.2T priority patent/FI3902803T3/fi
Priority to JP2021538127A priority patent/JP7418441B2/ja
Priority to LTEPPCT/US2019/068652T priority patent/LT3902803T/lt
Priority to CA3124952A priority patent/CA3124952A1/en
Priority to MX2021007829A priority patent/MX2021007829A/es
Priority to EA202191801A priority patent/EA202191801A1/ru
Priority to AU2019416349A priority patent/AU2019416349B2/en
Priority to SI201930515T priority patent/SI3902803T1/sl
Priority to BR112021012595-7A priority patent/BR112021012595A2/pt
Priority to IL284326A priority patent/IL284326B1/en
Priority to KR1020217023828A priority patent/KR20220051301A/ko
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Priority to RS20230240A priority patent/RS64135B1/sr
Priority to US17/418,442 priority patent/US20220144820A1/en
Priority to UAA202104321A priority patent/UA127525C2/uk
Priority to SG11202106637SA priority patent/SG11202106637SA/en
Priority to JOP/2021/0172A priority patent/JOP20210172A1/ar
Priority to CN201980092742.2A priority patent/CN113454085B/zh
Priority to DK19845796.2T priority patent/DK3902803T3/da
Priority to ES19845796T priority patent/ES2942310T3/es
Priority to PL19845796.2T priority patent/PL3902803T3/pl
Priority to EP19845796.2A priority patent/EP3902803B1/en
Priority to CR20210410A priority patent/CR20210410A/es
Publication of WO2020139991A1 publication Critical patent/WO2020139991A1/en
Priority to ZA2021/04423A priority patent/ZA202104423B/en
Priority to CONC2021/0009879A priority patent/CO2021009879A2/es
Priority to JP2023208546A priority patent/JP2024015340A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • Methionine adenosyltransferase which is also known as S- adenosylmethionine synthetase, is a cellular enzyme that catalyzes the synthesis of S- adenosyl methionine (SAM or AdoMet) from methionine and ATP; the catalysis is
  • SAM is the propylamino donor in polyamine biosynthesis, the principal methyl donor for DNA methylation, and is involved in gene transcription and cellular proliferation as well as the production of secondary
  • MAT1A and MAT2A encode two distinct catalytic MAT isoforms, respectively.
  • a third gene, MAT2B encodes a MAT2A regulatory subunit.
  • MAT1 A is specifically expressed in the adult liver, whereas MAT2A is widely distributed. Because MAT isoforms differ in catalytic kinetics and regulatory properties, MAT1A- expressing cells have considerably higher SAM levels than do MAT2A-expressing cells. It has been found that hypomethylation of the MAT2A promoter and histone acetylation causes upregulati on of MAT2A expression. See, e.g. M. Vazquez-Chantada el al. Gastroenterology 138 (2010) 1943-53; M. Frm et al, J. Hepatol. 59 (2013) 830-41; M. Frau et al. , Hepatology 56 (2012) 165-75; and R. M. Pascale et al, Transl. Gastroenterol. Hepatol. 3 (2016) 36.
  • MAT1A hepatocellular carcinoma
  • MAT2A hepatocellular carcinoma
  • the switch accompanied with up-regulation of MAT2B, results in lower SAM contents, which provide a growth advantage to hepatoma cells.
  • MAT2A plays a crucial role in facilitating the growth of hepatoma cells, it is a target for antineoplastic therapy.
  • silencing by using small interfering RNA substantially suppresses growth and induces apoptosis in hepatoma cells. See, e.g., T. Li et al, J. Cancer 7(10) (2016) 1317-1327.
  • Some cancer cell lines that are MTAP deficient are particularly sensitive to inhibition of MAT2A. Mar j on et at. (Cell Reports 15(3) (2016) 574-587). MTAP
  • methylthioadenosine phosphorylase is an enzyme widely expressed in normal tissues that catalyzes the conversion of methylthioadenosine (MTA) into adenine and 5- methylthioribose-1 -phosphate. The adenine is salvaged to generate adenosine
  • MTA can serve as an alternative purine source when de novo purine synthesis is blocked, e.g., with antimetabolites, such as L-alanosine.
  • MAT2A is dysregulated in additional cancers that lack MTAP-deletion, including hepatocellular carcinoma and leukemia.
  • Silencing of MAT2A expression via RNA- interference results in anti-proliferative effects in several cancer models.
  • H. Chen et al. Gastroenterology 133 (2007) 207-218; Q. Liu et al. Hepatol. Res. 37 (2007) 376-388.
  • MTAP deficiency is found not only in tissue culture cells but the deficiency is also present in primary leukemias, gliomas, melanomas, pancreatic cancers, non-small cell lung cancers (NSCLC), bladder cancers, astrocytomas, osteosarcomas, head and neck cancers, myxoid chondrosarcomas, ovarian cancers, endometrial cancers, breast cancers, soft tissue sarcomas, non-Hodgkin lymphoma, and mesotheliomas.
  • NSCLC non-small cell lung cancers
  • bladder cancers astrocytomas
  • osteosarcomas head and neck cancers
  • myxoid chondrosarcomas myxoid chondrosarcomas
  • ovarian cancers endometrial cancers
  • breast cancers soft tissue sarcomas
  • non-Hodgkin lymphoma non-Hodgkin lymphoma
  • This region also contains the tumor suppressor genes pl6INK4A (also known as CDKN2A) and pl5INK4B. These genes code for pl6 and pl5, which are inhibitors of the cyclin D-dependent kinases cdk4 and cdk6, respectively.
  • the pl6INK4A transcript can alternatively be alternative reading frame (ARF) spliced into a transcript encoding pl4ARF.
  • pl4ARF binds to MDM2 and prevents degradation of p53 (Pomerantz et al. (1998) Cell 92:713-723).
  • the 9p21 chromosomal region is of interest because it is frequently homozygously deleted in a variety of cancers, including leukemias, NSLC, pancreatic cancers, gliomas, melanomas, and mesothelioma.
  • deletion of the MTAP gene, but not pl6INK4A was reported to be indicative of a cancer at an early stage of development, whereas deletion of the genes encoding for pl6 and MTAP was reported to be indicative of a cancer at a more advanced stage of tumor development.
  • the MTAP gene was present at diagnosis but was deleted at a later time point (Garcia-Castellano et al, Clin. Cancer Res. 8(3) 2002 782-787).
  • the present disclosure provides compounds that inhibit MAT2A.
  • the compounds and their pharmaceutical compositions are useful in methods for treating various cancers, including those that are refractory to standard treatments, such as surgery, radiation therapy, chemotherapy, and hormonal therapy.
  • the present disclosure provides a compound according to formula I or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof:
  • L is O, S, NR, or a bond.
  • R is H or Ci-C6-alkyl.
  • R 1 is selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C3-C6- carbocyclyl, -(Ci-C6-alkyl)(C3-C6-carbocyclyl), and -(Ci-C6-alkyl)(C3-C6-cycloalkenyl) wherein any alkyl in R 1 is straight or branched.
  • R 1 is optionally substituted by 1-6 halo or 1-6 deuterium.
  • R and R 1 in combination with L represent a 3- to 6-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally substituted by one or more R A .
  • R 2 and R 3 are independently selected from the group consisting of C2-C6-alkynyl, Ce- Cio-aryl, C3-C6-carbocyclyl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), and 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S).
  • R 4 is selected from the group consisting ofH, Ci-C6-alkyl (optionally substituted by one or more halo, hydroxy or 3- to 14-membered heterocycloalkoxy (wherein 1-4
  • heterocycloalkoxy members are independently selected from N, O, and S)), -0(Ci-C6-alkyl) (optionally substituted by one or more halo), -OH, halo, -CN, -(Ci-C6-alkyl)NR A R B , and - NR A R B
  • R 5 is selected from the group consisting ofH, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6- alkenyl, C2-C6-alkynyl, halo, -CN, and -NR C R D .
  • R A and R B are independently selected from the group consisting ofH, -CN, -hydroxy, oxo, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, -NH2, -S(0)o-2-(Ci-C6-alkyl), - S(0)o-2-(C6-Cio-aryl), -C(0)(Ci-C 6 -alkyl), -C(0)(C 3 -Ci4-carbocyclyl), -C 3 -Ci4-carbocyclyl, - (Ci-C6-alkyl)(C 3 -Ci4-carbocyclyl), C6-Cio-aryl, 3- to 14-membered heterocycloalkyl and - (Ci-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycl
  • Each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl, heterocycloalkyl, and heteroaryl moiety of R A and R B is optionally substituted with one or more substituents selected from the group consisting of deuterium, hydroxy, halo, -NR’2 (wherein each R’ is independently selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C6-Cio-aryl, 3- to 14-membered heterocycloalkyl and -(Ci-C6-alkyl)-(3- to 14- membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected fromN, O, and S)), -NHC(0)(OCi-C6-alkyl), -
  • Each alkyl, alkenyl, aryl, and heterocycloalkyl substituent in R A and R B is optionally substituted with one or more substituents selected from the group consisting of deuterium, hydroxy, -OCi-C6-alkyl, halo, -NH2, -(Ci-C6-alkyl)NH2, -C(0)OH, CN, and oxo.
  • R c and R D are each independently selected from H and Ci-C6-alkyl.
  • the disclosure provides in another embodiment a pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof as described herein, and a
  • the disclosure provides a method for treating a cancer in a subject suffering therefrom, comprising administering to the subject an effective amount of a MAT2A inhibitor compound as described herein.
  • Yet another embodiment of the disclosure is a method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a cell, comprising introducing into the cell an effective amount of a compound, or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof, as described herein.
  • SAM S-adenosyl methionine
  • the disclosure in another embodiment, relates to a method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a subject, comprising administering to the subject an effective amount of at least one compound or a salt, tautomer, and/or isotopologue thereof as described herein.
  • SAM S-adenosyl methionine
  • the disclosure provides a method for treating a cancer in a subject suffering therefrom, wherein the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, the absence of the MTAP gene, or reduced function of MTAP protein, as compared to cancers where the MTAP gene or protein is present and/or fully functioning, the method comprising administering to the subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof, as described herein.
  • MTAP methylthioadenosine phosphorylase
  • the disclosure also provides in another embodiment a compound or a
  • SAM S-adenosyl methionine
  • the disclosure provides a compound or a
  • the disclosure also provides the use of a compound as described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.
  • a compound as described herein, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating cancer.
  • the compounds described herein are inhibitors of MAT2A.
  • the present disclosure thus relates not only to such compounds in conformity with Formula I, but also to their pharmaceutical compositions, tautomers, and isotopologues.
  • the compounds and compositions are useful in treating cancers.
  • Some cancers include various MTAP-deleted cancers, i.e., those cancers characterized by the absence or deletion of the MTAP gene/protein or reduced function of the MTAP protein.
  • Alkyl refers to straight, branched chain hydrocarbyl groups, from 1 to about 20 carbon atoms.
  • an alkyl can have from 1 to 10 carbon atoms or 1 to 6 carbon atoms.
  • Exemplary alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , - CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 )(CH 2 CH
  • substituted alkyl refers to alkyl substituted at one or more positions, for example, 1, 2, 3, 4, 5, or even 6 positions, which substituents are attached at any available atom to produce a stable compound, with substitution as described herein.
  • Optionally substituted alkyl refers to alkyl or substituted alkyl.
  • Each of the terms“halogen,”“halide,” and“halo” refers to -F, -Cl, -Br, or -I.
  • alkenyl refers to straight or branched chain hydrocarbyl groups including from 2 to about 20 carbon atoms having 1-3, 1-2, or at least one carbon to carbon double bond.
  • An alkenyl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • Substituted alkenyl refers to alkenyl substituted at 1 or more, e.g., 1, 2, 3, 4, 5, or even 6 positions, which substituents are attached at any available atom to produce a stable compound, with substitution as described herein.
  • Optionally substituted alkenyl refers to alkenyl or substituted alkenyl.
  • alkyne or“alkynyl” refers to a straight or branched chain unsaturated hydrocarbon having the indicated number of carbon atoms and at least one triple bond.
  • alkynyl group include, but are not limited to, acetylene, propyne, 1-butyne, 2-butyne, 1- pentyne, 2-pentyne, 1-hexyne, 2-hexyne, 3-hexyne, 1-heptyne, 2-heptyne, 3-heptyne, 1- octyne, 2-octyne, 3-octyne and 4-octyne.
  • An alkynyl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • Substituted alkynyl refers to an alkynyl substituted at 1 or more, e.g., 1, 2, 3, 4, 5, or even 6 positions, which substituents are attached at any available atom to produce a stable compound, with substitution as described herein.
  • Optionally substituted alkynyl refers to alkynyl or substituted alkynyl.
  • alkoxy refers to an -O-alkyl group having the indicated number of carbon atoms.
  • a (Ci-Ce)alkoxy group includes -O-methyl, -O-ethyl, -O-propyl, -O- isopropyl, -O-butyl, -O-seobutyl, -O-te/7-butyl, -O-pentyl, -O-isopentyl, -O-neopentyl, -O- hexyl, -O-isohexyl, and -O-neohexyl.
  • the term“carbocyclyl” refers to a monocyclic, bicycbc, tricyclic, or polycyclic, 3- to 14-membered ring system, which is either saturated, such as“cycloalkyl,” or unsaturated, such as“cycloalkenyl.”
  • the term“cycloalkenyl” refers specifically to cyclic alkenyl, such as C3-C6-cycloalkenyl.
  • the carbocyclyl may be attached via any atom. Carbocyclyl, for instance, also contemplates fused rings wherein, for instance, a carbocyclyl is fused to an aryl or heteroaryl ring as defined herein.
  • carbocyclyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, phenyl, naphthyl, anthracyl, benzofuranyl, and
  • a carbocyclyl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • “Substituted carbocyclyl” refers to carbocyclyl substituted at 1 or more, e.g., 1, 2, 3,
  • Optionally substituted carbocyclyl refers to carbocyclyl or substituted carbocyclyl.
  • “Aryl” when used alone or as part of another term means a carbocycbc aromatic group whether or not fused having the number of carbon atoms designated or if no number is designated, up to 14 carbon atoms, such as a C6-Ci4-aryl.
  • Particular aryl groups are phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like (see e.g. Lang’s Handbook of Chemistry (Dean, J. A., ed) 13 th ed. Table 7-2 [1985]).
  • a particular aryl is phenyl.
  • “Aryl” also includes aromatic ring systems that are optionally fused with a carbocyclyl ring, as herein defined. An aryl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • a "substituted aryl” is an aryl that is independently substituted with one or more substituents attached at any available atom to produce a stable compound, wherein the substituents are as described herein. “Optionally substituted aryl” refers to aryl or substituted aryl.
  • heteroatom refers to N, O, and S.
  • Compounds that contain N or S atoms can be optionally oxidized to the corresponding N-oxide, sulfoxide, or sulfone compounds.
  • Heteroaryl refers to a monocyclic aromatic ring structure containing 5 to 10, such as 5 or 6 ring atoms, or a bi cyclic aromatic group having 8 to 10 atoms, containing one or more, such as 1-4, 1-3, or 1-2, heteroatoms independently selected from the group consisting of O, S, and N.
  • Heteroaryl is also intended to include oxidized S or N, such as sulfmyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
  • a carbon or heteroatom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced.
  • heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, and indolyl.
  • a heteroaryl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • a "substituted heteroaryl” is a heteroaryl that is independently substituted, unless indicated otherwise, with one or more, e.g., 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, also 1 substituent, attached at any available atom to produce a stable compound, wherein the substituents are as described herein.
  • “Optionally substituted heteroaryl” refers to heteroaryl or substituted heteroaryl.
  • Heterocycloalkyl means a saturated or unsaturated non-aromatic monocyclic, bicyclic, tricyclic or polycyclic ring system that has from 3 to 14, such as 3 to 6, atoms in which from 1 to 4 carbon atoms in the ring are replaced by heteroatoms of O, S or N.
  • a heterocycloalkyl is optionally fused with aryl or heteroaryl of 5-6 ring members, and includes oxidized S or N, such as sulfmyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
  • the point of attachment of the heterocycloalkyl ring is at a carbon or heteroatom such that a stable ring is retained.
  • Examples of heterocycloalkyl groups include without limitation morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl,
  • a heterocycloalkyl group can be unsubstituted or optionally substituted with one or more substituents as described herein below.
  • Optionally substituted heterocycloalkyl denotes a heterocycloalkyl that is substituted with 1 to 3 substituents, e.g., 1, 2 or 3 substituents, attached at any available atom to produce a stable compound, wherein the substituents are as described herein.
  • Heterocycloalkoxy refers to an -O-heterocycloalkyl group having the indicated number of member atoms in a monocyclic, bicyclic, tricyclic or polycyclic ring system and where 1 to 4 carbon atoms in the ring are replaced by heteroatoms of O, S or N.
  • Optionally substituted heterocycloalkoxy refers to a heterocycloalkoxy group that is substituted with 1 to 3 substituents, e.g., 1, 2 or 3 substituents, attached at any available atom to produce a stable compound, wherein the substituents are as described herein.
  • nitrile or“cyano” can be used interchangeably and refer to a -CN group which is bound to a carbon atom of a heteroaryl ring, aryl ring and a heterocycloalkyl ring.
  • A“hydroxyl” or“hydroxy” refers to an -OH group.
  • the substituent -CO2H may be replaced with bioisosteric replacements such as:
  • R has the same definition as R A as defined herein. See, e.g.. THE PRACTICE OF MEDICINAL CHEMISTRY (Academic Press: New York, 1996), at page 203.
  • Compounds described herein can exist in various isomeric forms, including configurational, geometric, and conformational isomers, including, for example, cis- or trans- conformations.
  • the compounds may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers.
  • the term“isomer” is intended to encompass all isomeric forms of a compound of this disclosure, including tautomeric forms of the compound.
  • the compounds of the present disclosure may also exist in open-chain or cyclized forms. In some cases, one or more of the cyclized forms may result from the loss of water.
  • the specific composition of the open-chain and cyclized forms may be dependent on how the compound is isolated, stored or administered. For example, the compound may exist primarily in an open-chained form under acidic conditions but cyclize under neutral conditions. All forms are included in the disclosure.
  • a compound of the disclosure can be in the form of an optical isomer or a diastereomer. Accordingly, the disclosure encompasses compounds and their uses as described herein in the form of their optical isomers, diastereoisomers and mixtures thereof, including a racemic mixture.
  • Optical isomers of the compounds of the disclosure can be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology or via chemical separation of stereoisomers through the employment of optically active resolving agents.
  • stereoisomer means one stereoisomer of a compound that is substantially free of other stereoisomers of that compound.
  • a stereomerically pure compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
  • a stereomerically pure compound having two chiral centers will be substantially free of other diastereomers of the compound.
  • a typical stereomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, for example greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of the other stereoisomers of the compound, or greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of the other stereoisomers of the compound, or greater than about 99% by weight of one stereoisomer of the compound and less than about 1% by weight of the other stereoisomers of the compound.
  • the stereoisomer as described above can be viewed as composition comprising two stereoisomers that are present in their respective weight percentages described herein.
  • the term“isotopologue” is an isotopically enriched compound.
  • the term“isotopically enriched” refers to an atom having an isotopic composition other than the naturally abundant isotopic composition of that atom.
  • “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.
  • “isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope of a given atom in a molecule in the place of that atom's natural isotopic composition. For example, deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position.
  • the term“isotopic enrichment factor” refers to the ratio between the isotopic composition and the natural isotopic composition of a specified isotope.
  • a position designated as having deuterium typically has a minimum isotopic enrichment factor of, in particular embodiments, at least 1000 (15% deuterium incorporation), at least 2000 (30% deuterium incorporation), at least 3000 (45% deuterium incorporation), at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) at each designated deuterium atom.
  • the isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
  • the depicted structure controls. Additionally, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. In some cases, however, where more than one chiral center exists, the structures and names may be represented as single enantiomers to help describe the relative stereochemistry. Those skilled in the art of organic synthesis will know if the compounds are prepared as single enantiomers from the methods used to prepare them.
  • a“compound” is inclusive in that it encompasses a compound or a pharmaceutically acceptable salt, stereoisomer, isotopologue, and/or tautomer thereof.
  • a compound of Formula I or II includes a pharmaceutically acceptable salt of an isotopologue of the compound.
  • a“pharmaceutically acceptable salt” is a pharmaceutically acceptable, organic or inorganic acid or base salt of a compound of the disclosure.
  • Representative pharmaceutically acceptable salts include, e.g., alkali metal salts, alkali earth salts, ammonium salts, water-soluble and water-insoluble salts, such as the acetate, amsonate (4, 4-diaminostilbene-2, 2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate,
  • sulfosabcylate sulfosabcylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
  • a pharmaceutically acceptable salt can have more than one charged atom in its structure.
  • the pharmaceutically acceptable salt can have multiple counterions.
  • a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterions.
  • the terms“treat”,“treating” and“treatment” refer to the amelioration or eradication of a disease or symptoms associated with a disease. In certain embodiments, such terms refer to minimizing the spread or worsening of the disease resulting from the administration of one or more prophylactic or therapeutic agents to a patient with such a disease.
  • the terms“prevent,”“preventing,” and“prevention” refer to the prevention of the onset, recurrence, or spread of the disease in a patient resulting from the administration of a prophylactic or therapeutic agent.
  • a therapeutically effective amount with respect to a compound of the disclosure means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease.
  • the term can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of or synergizes with another therapeutic agent.
  • A“patient” or subject” includes an animal, such as a human, cow, horse, sheep, lamb, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig.
  • the animal is a mammal such as a non-primate and a primate (e.g., monkey and human).
  • a patient is a human, such as a human infant, child, adolescent or adult.
  • “Inhibitor” means a compound which prevents or reduces the amount of synthesis of SAM.
  • an inhibitor binds to MAT2A.
  • the inhibitor inhibits the function of MAT2A.
  • the present disclosure provides compounds and pharmaceutically acceptable salts, tautomers, and/or isotopologues thereof, wherein the compounds conform to formula I:
  • L is O, S, NR, or a bond.
  • R is H or Ci-C6-alkyl.
  • R 1 is selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C3-C6- carbocyclyl, -(Ci-C6-alkyl)(C3-C6-carbocyclyl), and -(Ci-C6-alkyl)(C3-C6-cycloalkenyl) wherein any alkyl in R 1 is straight or branched.
  • R 1 is optionally substituted by 1 - 6 halo or 1 - 6 deuterium.
  • R and R 1 in combination with L represent a 3- to 6-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally substituted by one or more R A .
  • R 2 and R 3 are independently selected from the group consisting of C2-C6-alkynyl, Ce- Cio-aryl, C3-C6-carbocyclyl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), and 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S).
  • R 4 is selected from the group consisting ofH, Ci-C6-alkyl (optionally substituted by one or more halo, hydroxy or 3- to 14-membered heterocycloalkoxy (wherein 1-4
  • heterocycloalkoxy members are independently selected from N, O, and S)), -0(Ci-C6-alkyl) (optionally substituted by one or more halo), -OH, halo, -CN, -(Ci-C6-alkyl)NR A R B , and - NR A R B
  • R 5 is selected from the group consisting ofH, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6- alkenyl, C2-C6-alkynyl, halo, -CN, and -NR C R D .
  • R A and R B are independently selected from the group consisting ofH, -CN, -hydroxy, oxo, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, -NH2, -S(0)o-2-(Ci-C6-alkyl), - S(0)o-2-(C6-Cio-aryl), -C(0)(Ci-C 6 -alkyl), -C(0)(C 3 -Ci4-carbocyclyl), -C 3 -Ci4-carbocyclyl, - (Ci-C6-alkyl)(C 3 -Ci4-carbocyclyl), C6-Cio-aryl, 3- to 14-membered heterocycloalkyl and - (Ci-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 heterocycl
  • Each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl, heterocycloalkyl, and heteroaryl moiety of R A and R B is optionally substituted with one or more substituents selected from the group consisting of deuterium, hydroxy, halo, -NR’2 (wherein each R’ is independently selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C2-C6- alkynyl, C6-Cio-aryl, 3- to 14-membered heterocycloalkyl and -(Ci-C6-alkyl)-(3- to 14- membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), -NHC(0)(OCi-C6-alkyl), -NO
  • Each alkyl, alkenyl, aryl, and heterocycloalkyl substituent in R A and R B is optionally substituted with one or more substituents selected from the group consisting of hydroxy, -OCi-C6-alkyl, halo, -NH2, -(Ci-C6-alkyl)NH2, -C(0)OH, CN, and oxo.
  • R c and R D are each independently selected from H and Ci-C6-alkyl.
  • R 4 is selected from the group consisting ofH, Ci-C6-alkyl (optionally substituted by one or more halo, hydroxy or 3- to 14-membered
  • heterocycloalkoxy (wherein 1-4 heterocycloalkoxy members are independently selected from N, O, and S)), -0(Ci-C6-alkyl), -(Ci-C6-alkyl)NR A R B , and -NR A R B (wherein R A and R B are independently selected from H and Ci-C6-alkyl); and R 5 is selected from the group consisting of H, Ci-C6-alkyl, Ci-C6-alkoxy, and -NR C R D .
  • R 4 and R 5 are H.
  • R 4 is H or R 5 is H.
  • each of R 4 and R 5 is H.
  • R 2 is optionally substituted C6-C10- aryl or optionally substituted 5- to 10-membered heteroaryl.
  • R 2 is optionally substituted C6-C 10-aryl, such as optionally substituted phenyl.
  • R 2 is optionally substituted 5- to 10-membered heteroaryl, and wherein 1 ring member is N.
  • R 2 is an optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 6-membered heteroaryl, an example of which is optionally substituted pyridyl.
  • R 3 is optionally substituted 3- to 14-membered heterocycloalkyl or optionally substituted 5- to 10-membered heteroaryl.
  • R 3 are selected from the group consisting of benzothiazolyl, benzoisothiazolyl, benzoxazolyl, pyridinyl, pyridinonyl, pyridazinyl, benzimidazolyl, benzotriazolyl, indazolyl, quinoxabnyl, quinobnyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, triazolopyridinyl, cinnobnyl, isoxazolyl, pyrazolyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzodioxinyl, and tetrahydrobenzodioxinyl,
  • R 3 is optionally substituted C6-Cio-aryl.
  • An example is optionally substituted phenyl.
  • R 2 is optionally substituted phenyl and R 3 is optionally substituted 3- to 14-membered heterocycloalkyl or optionally substituted 5- to 10-membered heteroaryl.
  • the disclosure provides a Formula I compound wherein L is O or NR.
  • R 1 is optionally substituted Ci-C6-alkyl or optionally substituted C3-C6-carbocyclyl.
  • An example of R 1 is Ci-C3-alkyl that is optionally substituted by 1-3 F.
  • a subset of Formula I compounds are those in which L is O or NR and R is H; R 1 is Ci-C3-alkyl that is optionally substituted by 1 - 3 F; R 2 is optionally substituted 3- to 14-membered heterocycloalkyl or optionally substituted 5- to 10- membered heteroaryl (wherein 1 heterocycloalkyl or heteroaryl member is N) or optionally substituted C6-Cio-aryl; R 3 is optionally substituted 3- to 14-membered heterocycloalkyl or optionally substituted 5- to 10-membered heteroaryl wherein 1 to 3 heterocycloalkyl or heteroaryl members are independently selected from N, O, and S; and each of R 4 and R 5 is H.
  • L is NR.
  • the disclosure provides additional specific examples of Formula I compounds, and their pharmaceutically acceptable salts, tautomers, and/or isotopologues as set forth in Table 2 below.
  • composition also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a
  • composition further contains, in accordance with accepted practices of pharmaceutical compounding, one or more additional therapeutic agents, pharmaceutically acceptable excipients, diluents, adjuvants, stabilizers, emulsifiers, preservatives, colorants, buffers, flavor imparting agents.
  • the pharmaceutical composition comprises a compound selected from those illustrated in Table 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer, and/or isotopologue thereof, and a pharmaceutically acceptable carrier.
  • composition of the present disclosure is formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular subject being treated, the clinical condition of the subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • The“therapeutically effective amount” of a compound (or a pharmaceutically acceptable salt, stereoisomer, tautomer, and/or isotopologue thereof that is administered is governed by such considerations, and is the minimum amount necessary to exert a cytotoxic effect on a cancer, or to inhibit MAT2A activity, or both. Such amount may be below the amount that is toxic to normal cells, or the subject as a whole.
  • the initial therapeutically effective amount of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure that is administered is in the range of about 0.01 to about 200 mg/kg or about 0.1 to about 20 mg/kg of patient body weight per day, with the typical initial range being about 0.3 to about 15 mg/kg/day.
  • Oral unit dosage forms, such as tablets and capsules may contain from about 1 mg to about 1000 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In another embodiment, such dosage forms contain from about 50 mg to about 500 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure.
  • such dosage forms contain from about 25 mg to about 200 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In still another embodiment, such dosage forms contain from about 10 mg to about 100 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure. In a further embodiment such dosage forms contain from about 5 mg to about 50 mg of a compound (or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof) of the present disclosure.
  • compositions can be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques.
  • Suitable oral compositions in accordance with the disclosure include without limitation tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, syrups or elixirs.
  • pharmaceutical compositions suitable for single unit dosages that comprise a compound of the disclosure or its pharmaceutically acceptable stereoisomer, salt, or tautomer and a pharmaceutically acceptable carrier.
  • compositions suitable for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
  • liquid formulations of the compounds contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically palatable preparations of the MAT2A inhibitor.
  • a compound of the present disclosure in admixture with non toxic pharmaceutically acceptable excipients is used for the manufacture of tablets.
  • excipients include without limitation inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract and thereby to provide a sustained therapeutic action over a desired time period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin or olive oil.
  • a compound of the present disclosure is admixed with excipients suitable for maintaining a stable suspension.
  • excipients include without limitation are sodium carboxymethylcellulose, methylcellulose,
  • Oral suspensions can also contain dispersing or wetting agents, such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
  • dispersing or wetting agents such as naturally- occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol,
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending a compound of the present disclosure in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide a compound of the present disclosure in admixture with a dispersing or wetting agent, suspending agent and one or more
  • preservatives Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • compositions of the present disclosure may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable, an aqueous suspension or an oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • Suitable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono-or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of general Formula I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary
  • Such materials are cocoa butter and polyethylene glycols.
  • compositions for parenteral administrations are administered in a sterile medium.
  • the parenteral formulation can either be a suspension or a solution containing dissolved drug.
  • Adjuvants such as local anesthetics, preservatives and buffering agents can also be added to parenteral compositions.
  • the MAT2A enzyme catalyzes the synthesis of S-adenosyl methionine (SAM) from methionine and ATP in cells. Accordingly, in another embodiment of the present disclosure there is provided a method of inhibiting in a cell the synthesis of SAM comprising introducing into the cell an effective amount of a compound of Formula I or a
  • the cell is in a subject.
  • a Formula I compound is used to identify other compounds that are inhibitors of MAT2A, for example, in a competition assay for binding to MAT2A or for the inhibition of SAM production. Binding to MAT2A or the inhibition of SAM production by a test compound having a detectable label can be measured with and without the presence of an unlabeled compound of the present disclosure.
  • the present disclosure also provides a method for treating a cancer in a subject suffering therefrom, comprising administering to the subject an effective amount of a MAT2A inhibitor compound as described herein.
  • the MAT2A inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the subject is a mammal, such as a human.
  • the cancer is an MTAP-deleted cancer.
  • the cancer as one selected from the group consisting of mesothelioma, neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroidea carcinoma, papillary thyroidea carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors, head and neck cancer, lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (C ALL), chronic lymphatic leukemia (C
  • the cancer is selected from lung cancer, non-small cell lung cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma,
  • medulloblastomas meningiomas, squamous cell carcinomas, pituitary adenomas, including resistant and/or refractory versions of any of the above cancers, and a combination of one or more of the above cancers.
  • the cancer is selected from the group consisting of B- cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer, melanoma and breast cancer.
  • B-ALL B- cell acute lymphocytic leukemia
  • the lung cancer is non-small cell lung cancer, small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung.
  • the breast cancer is triple negative breast cancer (TNBC).
  • TNBC triple negative breast cancer
  • the brain cancer is a brain tumor selected from the group consisting of glioma, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumors, and craniopharyngioma.
  • the cancer is a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma (ATLL).
  • the expression adult T-cell leukemia/lymphoma refers to a rare and often aggressive T-cell lymphoma that can be found in the blood (leukemia), lymph nodes (lymphoma), skin, or multiple areas of the body.
  • methylthioadenosine phosphorylase is an enzyme found in all normal tissues that catalyzes the conversion of methylthioadenosine (MTA) into adenine and 5-methylthioribose-l -phosphate.
  • MTA methylthioadenosine
  • the adenine is salvaged to generate adenosine monophosphate, and the 5-methylthioribose-l -phosphate is converted to methionine and formate. Because of this salvage pathway, MTA can serve as an alternative purine source when de novo purine synthesis is blocked, e.g., with antimetabolites, such as L- alanosine.
  • Many human and murine malignant cells lack MTAP activity.
  • MTAP deficiency is not only found in tissue culture cells but the deficiency is also present in primary leukemias, gliomas, melanomas, pancreatic cancers, non-small cell lung cancers (NSCLC), bladder cancers, astrocytomas, osteosarcomas, head and neck cancers, myxoid
  • MTAP null or MTAP-deleted cancer is a cancer in which the MTAP gene has been deleted or lost or otherwise deactivated or a cancer in which the MTAP protein has a reduced or impaired function, or a reduced presence.
  • a method for treating a cancer in a subject wherein the cancer is characterized by a reduction or absence of MTAP expression or absence of the MTAP gene or reduced function of MTAP protein as compared to cancers where the MTAP gene and/or protein is present and fully functioning, or as compared to cancers with the wild type MTAP gene.
  • the method comprises administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof.
  • a method of treating an MTAP deleted cancer in a subject comprising administering to the subject an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the MTAP deleted cancer is selected from leukemia, glioma, melanoma, pancreatic cancer, non small cell lung cancer (NSCLC), bladder cancer, astrocytoma, osteosarcoma, head and neck cancer, myxoid chondrosarcoma, ovarian cancer, endometrial cancer, breast cancer, soft tissue sarcoma, lymphoma, and mesothelioma.
  • the MTAP deleted cancer is pancreatic cancer.
  • the MTAP deleted cancer is selected from bladder cancer, melanoma, brain cancer, lung cancer, pancreatic cancer, breast cancer, liver cancer, esophageal cancer, gastric cancer, colon cancer, head and neck cancer, kidney cancer, colon cancer, diffuse large B cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), glioblastoma multiforme (GBM), and non-small cell lung cancer (NSCLC).
  • DLBCL diffuse large B cell lymphoma
  • ALL acute lymphoblastic leukemia
  • MCL mantle cell lymphoma
  • GBM glioblastoma multiforme
  • NSCLC non-small cell lung cancer
  • an embodiment of the present disclosure provides a method for treating a cancer in a subject wherein the cancer is characterized by reduction or absence of MTAP expression or absence of the MTAP gene or reduced function of MTAP protein, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I, wherein said cancer is further characterized by the presence of mutant KRAS or mutant p53.
  • a method of treating an MTAP null cancer having a mutant KRAS or mutant p53 in a subject comprising administering to the subject an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, tautomer, and/or isotopologue thereof.
  • the cancer is MTAP null and KRAS mutant, MTAP null and p53 mutant, or each of MTAP null, KRAS mutant and p53 mutant.
  • mutant KRAS or“KRAS mutation” refers to a KRAS protein incorporating an activating mutation that alters its normal function and the gene encoding such a protein.
  • a mutant KRAS protein may incorporate a single amino acid substitution at position 12 or 13.
  • the KRAS mutant incorporates a G12X or G13X substitution, wherein X represents any amino acid change at the indicated position.
  • the substitution is G12V, G12R, G12C or G13D.
  • the substitution is G13D.
  • “mutant p53” or“p53 mutation” is meant p53 protein (or gene encoding said protein) incorporating a mutation that inhibits or eliminates its tumor suppressor function.
  • said p53 mutation is,
  • the foregoing cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, head and neck cancer, gastric cancer, breast cancer, colon cancer or ovarian cancer.
  • NSCLC non-small cell lung cancer
  • the compounds disclosed herein are useful as ligands for degradation of disease-associated proteins.
  • An example of this approach is PROTACs (PROteolysis TArgeting Chimeras).
  • PROTACs are bifunctional molecules that comprise both a ligand moiety selected from one of the compounds disclosed herein, which is capable of binding the target protein, and a ligase targeting moiety, such as a peptide portion (referred to as the degron) that is recognized and polyubiquitinated by E3 ligase.
  • the PROTAC non-covalently binds to a target protein, and recruits E3 ligase via the degron, which results in polyubiquination and degradation of the bound target.
  • a number of publications describe the pre-clinical use of PROTACs in a variety of therapeutic areas including oncology. See, e.g., Lu et al. Chemistry & Biology 22 (2015) 755-763. [00123] ASPECTS
  • L is O, S, NR, or a bond
  • R is H or Ci-C6-alkyl
  • R 1 is selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C3-C6- carbocyclyl, -(Ci-C6-alkyl)(C3-C6-carbocyclyl), and -(Ci-C6-alkyl)(C3-C6- cycloalkenyl) wherein
  • any alkyl in R 1 is straight or branched
  • R 1 is optionally substituted by 1 - 6 halo
  • R and R 1 in combination with L represent a 3- to 6-membered heterocycloalkyl (wherein 1-4 ring members are independently selected from N, O, and S) optionally substituted by one or more R A ;
  • R 2 and R 3 are independently selected from the group consisting of C6-C 10-aryl, C3-C6- carbocyclyl, 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), and 3- to 14-membered heterocycloalkyl (wherein 1-4 heterocycloalkyl members are independently selected from N, O, and S), wherein R 2 and R 3 are independently and optionally substituted by one or more
  • R 4 is selected from the group consisting of H, Ci-C6-alkyl (optionally substituted by one or more halo), -0(Ci-C6-alkyl) (optionally substituted by one or more halo), -OH, halo, -CN, -(Ci-C6-alkyl)NR A R B , and -NR A R B ;
  • R 5 is selected from the group consisting of H, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, halo, -CN, and -NR C R D ;
  • R A and R B are independently selected from the group consisting of H, -CN, -hydroxy, oxo, Ci-C6-alkyl, Ci-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, -NH2, -S(0)o-2-(Ci-C6- alkyl), -S(0)o-2-(Ce-C 10-aryl), -C(0)(Ci-C 6 -alkyl), -C(0)(C 3 -Ci4-carbocyclyl), -C 3 - Ci4-carbocyclyl, -(Ci-C6-alkyl)(C 3 -Ci4-carbocycl
  • each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl, heterocycloalkyl, and heteroaryl moiety of R A and R B is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halo, -NR’ 2 (wherein each R’ is independently selected from the group consisting of Ci-C6-alkyl, C2-C6-alkenyl, C2- C6-alkynyl, C6-Cio-aryl, 3- to 14-membered heterocycloalkyl and -(Ci-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1-4 ring members are independently selected from N, O, and S), and 5- to 10-membered heteroaryl (wherein 1-4 heteroaryl members are independently selected from N, O, and S), -NHC(0)(0Ci-C6-alkyl), - NO2, -CN,
  • R c and R D are each independently selected from H and Ci-C6-alkyl
  • Aspect 2 The compound according to Aspect 1, wherein
  • R 4 is selected from the group consisting of H, Ci-C6-alkyl optionally substituted by one or more halo, -0(Ci-C6-alkyl), -(Ci-C6-alkyl)NR A R B , and -NR A R B (wherein R A and R B are independently selected from H and Ci-C6-alkyl); and
  • R 5 is selected from the group consisting ofH, Ci-C6-alkyl, Ci-C6-alkoxy, and -NR C R D .
  • Aspect 3 The compound according to Aspect 1 or 2, wherein at least one of R 4 and R 5 is H.
  • Aspect 4 The compound according to any one of Aspects 1 - 3, wherein R 4 is H.
  • Aspect 5 The compound according to any one of Aspects 1 - 4, wherein R 5 is H.
  • Aspect 6 The compound according to any one of Aspects 1 - 5, wherein each of R 4 and R 5 is H.
  • Aspect 7 The compound according to any one of Aspects 1 to 6, wherein R 2 is C6-Cio-aryl or 5- to 10-membered heteroaryl.
  • Aspect 8 The compound according to Aspect 7, wherein R 2 is C6-Cio-aryl.
  • Aspect 9 The compound according to Aspect 8, wherein R 2 is phenyl.
  • Aspect 10 The compound according to Aspect 7, wherein R 2 is 5- to 10- membered heteroaryl, and wherein 1 ring member is N.
  • Aspect 11 The compound according to Aspect 10, wherein R 2 is a 5- or 6- membered heteroaryl.
  • Aspect 12 The compound according to Aspect 10 or 11, wherein R 2 is a 6- membered heteroaryl.
  • Aspect 13 The compound according to any one of Aspects 10 - 12, wherein R 2 is pyridyl.
  • Aspect 14 The compound according to any one of Aspects 1 to 12, wherein R 3 is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl.
  • Aspect 15 The compound according to Aspect 14, wherein R 3 is selected from the group consisting of benzothiazolyl, benzoisothiazolyl, benzoxazolyl, pyridinyl, pyridinonyl, pyradazinyl, benzimidazolyl, benzotriazolyl, indazolyl, quinoxalinyl, quinolinyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, triazolopyridinyl, cinnolinyl, isoxazolyl, pyrazolyl, benzofuranyl, dihydrobenzofuranyl, dihydrobenzodioxinyl, and
  • Aspect 16 The compound according to any one of Aspects 1 to 12, wherein R 3 is C6-Cio-aryl.
  • Aspect 17 The compound according to Aspect 16, wherein R 3 is phenyl.
  • Aspect 18 The compound according to any one of Aspects 1 to 6, wherein R 2 is phenyl and R 3 is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl.
  • Aspect 19 The compound according to any one of Aspects 1 to 18, wherein L is O or NR.
  • Aspect 20 The compound according to Aspect 19, wherein R 1 is Ci-C6-alkyl or C3-C6-carbocyclyl.
  • Aspect 21 The compound according to Aspect 19 or 20, wherein R 1 is C1-C3- alkyl that is optionally substituted by 1 - 3 F.
  • Aspect 22 The compound according to Aspect 1, wherein
  • L is O or NR and R is H;
  • R 1 is Ci-C3-alkyl that is optionally substituted by 1 - 3 F;
  • R 2 is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl (wherein 1 heterocycloalkyl or heteroaryl member is N) or C6-C 10-aryl;
  • R 3 is 3- to 14-membered heterocycloalkyl or 5- to 10-membered heteroaryl wherein 1 to 3 heterocycloalkyl or heteroaryl members are independently selected from N, O, and S; and
  • each of R 4 and R 5 is H.
  • Aspect 23 The compound according to Aspect 22, wherein L is NR.
  • Aspect 24 The compound according to Aspect 1, wherein the compound is selected from the following table:
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of Aspects 1 to 24 or a
  • Aspect 26 A method for treating a cancer in a subject suffering therefrom, comprising administering to the subject an effective amount of a MAT2A inhibitor compound according to any one of Aspects 1 - 24.
  • Aspect 27 The method according to Aspect 26, wherein the cancer is an MTAP-deleted cancer.
  • Aspect 28 A method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a cell, comprising introducing into the cell an effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of Aspects 1 to 24.
  • SAM S-adenosyl methionine
  • Aspect 29 The method according to Aspect 28, wherein the cell is in a subject.
  • Aspect 30 A method for inhibiting the synthesis of S-adenosyl methionine (SAM) in a subject, comprising administering to the subject an effective amount of at least one compound or a salt thereof according to any one of Aspects 1 to 24.
  • SAM S-adenosyl methionine
  • Aspect 31 A method for treating a cancer in a subj ect suffering therefrom, comprising administering to the subject an effective amount of a compound according to any one of Aspects 1 to 24.
  • Aspect 32 The method according to Aspect 31, wherein the cancer is an MTAP-deleted cancer.
  • Aspect 33 The method according to any one of Aspects 26, 27, 31, and 32, wherein the cancer is selected from the group consisting of mesothelioma, neuroblastoma, rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroidea carcinoma, papillary thyroidea carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors, lymphoma, head and neck cancer, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia,
  • Aspect 34 The method according to Aspect 31 or 32, wherein the cancer is selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer, melanoma, and breast cancer.
  • B-ALL B-cell acute lymphocytic leukemia
  • mesothelioma mesothelioma
  • lymphoma pancreatic carcinoma
  • lung cancer gastric cancer
  • esophageal cancer esophageal cancer
  • bladder carcinoma brain cancer
  • head and neck cancer melanoma
  • breast cancer selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer
  • Aspect 35 The method according to Aspect 34, wherein the cancer is a lung cancer selected from the group consisting of non-small cell lung cancer, small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung.
  • Aspect 36 The method according to Aspect 34, wherein cancer is a brain tumor selected from the group consisting of glioma, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumors, and craniopharyngioma.
  • Aspect 37 The method according to Aspect 34, wherein the cancer is triple negative breast cancer (TNBC).
  • TNBC triple negative breast cancer
  • Aspect 38 The method according to Aspect 34, wherein the cancer is a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and adult T-cell leukemia/lymphoma.
  • Aspect 39 A method for treating a cancer in a subject suffering therefrom, wherein the cancer is characterized by a reduction or absence of methylthioadenosine phosphorylase (MTAP) gene expression, the absence of the MTAP gene, or reduced function of MTAP protein, as compared to cancers where the MTAP gene or protein is present and/or fully functioning, the method comprising administering to the subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to any one of Aspects 1 to 24.
  • MTAP methylthioadenosine phosphorylase
  • Aspect 40 A compound according to any one of Aspects 1 to 24, or a pharmaceutically acceptable salt thereof, for inhibiting the synthesis of S-adenosyl methionine (SAM).
  • SAM S-adenosyl methionine
  • Aspect 41 A compound according to any one of Aspects 1 to 24, or a pharmaceutically acceptable salt thereof, for treating a cancer in a subject suffering therefrom.
  • Aspect 42 The compound according to Aspect 41, wherein the cancer is an MTAP-deleted cancer.
  • Aspect 43 The compound according to Aspect 41 or 42, wherein the cancer is selected from the group consisting of mesothelioma, neuroblastoma, rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroidea carcinoma, papillary thyroidea carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors, lymphoma, head and neck cancer, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML),
  • ALL
  • Aspect 44 The compound according to Aspect 41 or 42, wherein the cancer is selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), mesothelioma, lymphoma, pancreatic carcinoma, lung cancer, gastric cancer, esophageal cancer, bladder carcinoma, brain cancer, head and neck cancer, melanoma, and breast cancer.
  • B-ALL B-cell acute lymphocytic leukemia
  • mesothelioma mesothelioma
  • lymphoma pancreatic carcinoma
  • lung cancer gastric cancer
  • esophageal cancer bladder carcinoma
  • brain cancer head and neck cancer
  • melanoma melanoma
  • breast cancer breast cancer.
  • Aspect 45 The compound according to Aspect 44, wherein the cancer is a lung cancer selected from the group consisting of non-small cell lung cancer, small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung.
  • Aspect 46 The compound according to Aspect 44, wherein the cancer is triple negative breast cancer (TNBC).
  • TNBC triple negative breast cancer
  • Aspect 47 The compound according to Aspect 44, wherein the cancer is a brain tumor selected from the group consisting of glioma, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumors, and craniopharyngioma.
  • Aspect 48 The compound according to any one of Aspects 41 to 43, wherein the cancer is a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma.
  • a lymphoma selected from the group consisting of mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma.
  • the reagents and solvents were purchased from commercial sources (such as Alfa, Acros, Sigma Aldrich, TCI and Shanghai Chemical Reagent Company), and used without further purification unless otherwise specified. Flash chromatography was performed on an Ez Purifier III using column with silica gel particles of 200-300 mesh. Analytical and preparative thin layer chromatography (TLC) plates were HSGF 254 (0.15-0.2 mm thickness, Shanghai Anbang Company, China). Nuclear magnetic resonance (NMR) spectra were obtained on a Brucker AMX-400 NMR (Brucker,
  • compound 1.8 was chlorinated to give aryl-chloride 1.10, and the desired Ri was installed via nucleophilic aromatic substitution to yield final compounds of structure 1.11 (Method C).
  • compound 1.8 was activated using BOP, and the desired N-linked Ri was installed via nucleophilic aromatic substitution to yield final compounds of structure 1.12 (Method D).
  • Step A 5-amino-6-bromo-4-chloropyridazin-3(2H)-one
  • Step B 5-amino-6-bromo-4-chloro-2-(2-methyl-2H-indazol-5-yl)pyridazin-
  • Step C ethyl (E)-3-(4-amino-5-chloro-l-(2-methyl-2H-indazol-5-yl)-6-oxo- l,6-dihydropyridazin-3-yl)acrylate
  • Step D 4-chloro-2-(2-methyl-2H-indazol-5-yl)pyrido[3,2-c]pyridazine-
  • 6-oxo- l,6-dihydropyridazin-3-yl)acrylate 400 mg, 1.07 mmol, 1.0 eq.
  • EtOH 10 mL
  • K2CO3 295 mg, 2.14 mmol, 2.0 eq.
  • the reaction mixture was stirred at 80°C for 3 hrs.
  • ice water (30 mL) was added and the mixture was extracted with EtOAc (30 mL x 3).
  • Step F 4-(4-chlorophenyl)-6-(cyclopropylmethoxy)-2-(2-methyl-2H-indazol-
  • Step C 4-chloro-6-hydroxy-2-(2-methyl-2H-indazol-5-yl)-8- (trifluoromethyl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Example 102 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2-methyl-2H- indazol-5-yl)-8-(trifluoromethyl)pyrido[3,2-c]pyridazin-3(2H)-one (Example 102) was synthesized from 2-(4-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and 2,2-difluoroethyl trifluoromethanesulfonate via general procedure I (Step E, F).
  • Step G 6-chloro-4-(4-chlorophenyl)-2-(2-methyl-2H-indazol-5-yl)pyrido[3,2- c]pyridazin-3(2H)-one
  • Step H 4-(4-chlorophenyl)-6-(ethylamino)-2-(2-methyl-2H-indazol-5- yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step I 2-(2-methyl-2H-indazol-5-yl)-4-(6-methylpyridin-3-yl)-6-((2,2,2- trifluoroethyl)amino)pyrido[3,2-c]pyridazin-3(2H)-one (Example 301)
  • Step B 6-(methyl-d3)pyridin-3-ol
  • Step C 6-(methyl-d3)pyridin-3-yl trifluoromethanesulfonate
  • Step D (6-(methy l-d3)pyri din-3 -yl)boronic acid
  • the desired R3 group was introduced using an Ullmann coupling (Method A) or a Chan-Lam coupling (Method B) to afford compounds of structure 2.8.
  • Compound 2.5 could be activated with BOP and reacted with the desired Ri-amine to afford heterocycle 2.9 (Method C).
  • the benzyl group was removed using t- BuOK to afford heterocycle 2.10 and the desired R3 group was introduced using an Ullmann coupling to afford compounds of structure 2.11.
  • Step A 5-amino-2-benzyl-6-bromo-4-chloropyridazin-3(2H)-one
  • Step B ethyl (E)-3-(4-amino-l-benzyl-5-chloro-6-oxo-l,6-dihydropyridazin-
  • Step C 2-benzyl-4-chloropyrido[3,2-c]pyridazine-3,6(2H,5H)-dione
  • Step D 2-benzyl-4-(4-(difluoromethoxy)phenyl)pyrido[3,2-c]pyridazine-
  • Step E 2-benzyl-6-chloro-4-(4-(difluoromethoxy)phenyl)pyrido[3,2- c]pyridazin-3(2H)-one
  • Step F 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)pyrido[3,2- c]pyridazin-3(2H)-one
  • Step G 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2,3- dimethyl-2H-indazol-5-yl)pyrido[3,2-c]pyridazin-3(2H)-one (Method A)
  • Step G 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(l-methyl- lH-benzo[d]imidazol-6-yl)pyrido[3,2-c]pyridazin-3(2H)-one (Method B)
  • Step H 2-benzyl-4-(6-(difluoromethyl)pyri din-3 -yl)-6-((ethyl- d5)amino)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step I 4-(6-(difluoromethyl)pyridin-3-yl)-6-((ethyl-d5)amino)pyrido[3,2- c]pyridazin-3(2H)-one
  • Step J 4-(6-(difluoromethyl)pyridin-3-yl)-6-((ethyl-d5)amino)-2-(2-(methyl- d3)-2H-indazol-5-yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step A 5-amino-6-bromo-4-chloro-2-(4-methoxybenzyl)pyridazin-3(2H)-one
  • Step A To a solution of 5-amino-6-bromo-4-chloropyridazin-3(2H)-one (2.0 g, 8.91 mmol, 1.0 eq.) and K2CO3 (2.5 g, 17.8 mmol, 2.0 eq.) in DMF (20 mL) was added PMBC1 (1.3 mL, 9.8 mmol, 1.1 eq.), the reaction mixture stirred at 80 °C for 14hrs.
  • Step B ethyl (E)-3-(4-amino-5-chloro-l-(4-methoxybenzyl)-6-oxo-l,6- dihydropyridazin-3-yl)acrylate
  • Step C 4-chloro-2-(4-methoxybenzyl)pyrido[3,2-c]pyridazine-3,6(2H,5H)- dione
  • Step D 4-(6-(difluoromethyl)pyridin-3-yl)-2-(4-methoxybenzyl)pyrido[3,2- c]pyridazine-3,6(2H,5H)-dione
  • Step E 4-(6-(difluoromethyl)pyridin-3-yl)-2-(4-methoxybenzyl)-6-((2,2,2- trifluoroethyl)amino)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step F 4-(6-(difluoromethyl)pyridin-3-yl)-6-((2,2,2- trifluoroethyl)amino)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step G 4-(6-(difluoromethyl)pyridin-3-yl)-2-(4-(methoxy-d3)phenyl)-6- ((2,2,2-trifluoroethyl)amino)pyrido[3,2-c]pyridazin-3(2H)-one (Example 322)
  • Step A 5-amino-4-chloro-2-(2-methyl-2H-indazol-5-yl)-6-vinylpyridazin-
  • Step B 4-amino-5-chloro-l-(2-methyl-2H-indazol-5-yl)-6-oxo-l,6- dihydropyridazine-3-carbaldehyde
  • Step C 4-amino-5-(4-(difluoromethoxy)phenyl)-l-(2-methyl-2H-indazol-5- yl)-6-oxo-l,6-dihydropyridazine-3-carbaldehyde
  • Step D 4-(4-(difluoromethoxy)phenyl)-7-fluoro-2-(2-methyl-2H-indazol-5- yl)pyrido[3,2-c]pyridazine-3,6(2H,5H)-dione
  • 4-amino-5-(4-(difluoromethoxy)phenyl)-l-(2-methyl-2H- indazol-5-yl)-6-oxo-l,6-dihydropyridazine-3-carbaldehyde 150 mg, 0.36 mmol, 1.0 eq.
  • ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate 132 mg, 0.55 mmol, 1.5 eq.
  • Step A 4-(4-aminophenyl)-2-(2-methyl-2H-indazol-5-yl)pyrido[3,2- c]pyridazine-3,6(2H,5H)-dione
  • Step B 4-(4-bromophenyl)-2-(2-methyl-2H-indazol-5-yl)pyrido[3,2- c]pyridazine-3,6(2H,5H)-dione
  • Step A 2-(3-bromo-2-methyl-2H-indazol-5-yl)-6-(2,2-difluoroethoxy)-4-(4-
  • Step B 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(3-
  • Step A 4-chloro-6-(2,2-difluoroethoxy)-2-(2-methyl-2H-indazol-5- yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step B 4-cyclohexyl-6-(2,2-difluoroethoxy)-2-(2-methyl-2H-indazol-5- yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step A l-(5-bromo-2-methyl-2H-indazol-3-yl)ethanol
  • Step B 5-bromo-3-ethyl-2-methyl-2H-indazole
  • Step A 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-8-
  • Step B 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2-methyl-
  • Step C 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-8-
  • Step A (6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2-methyl-
  • Step B 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-8-
  • Step A 6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2-methyl-
  • Step B 8-amino-6-(2,2-difluoroethoxy)-4-(4-(difluoromethoxy)phenyl)-2-(2- methyl-2H-indazol-5-yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step A 6-(2,2-difluoroethoxy)-2-(2-methyl-2H-indazol-5-yl)-4-
  • Step B 6-(2,2-difluoroethoxy)-4-ethynyl-2-(2-methyl-2H-indazol-5- yl)pyrido[3,2-c]pyridazin-3(2H)-one
  • Step C 4-((lH-pyrazol-3-yl)ethynyl)-6-(2,2-difluoroethoxy)-2-(2-methyl-2H- indazol-5 -y l)py rido [3 ,2-c] py ridazin-3(2H)-one
  • Mat2A protein was expressed by recombinant baculovirus in SF9 infected cells using the Bac to Bac system cloned into the pFASTBACl vector (Invitrogen, Carlsbad, CA). Recombinant MAT2A was isolated from the cell lysate of 150 g of infected cells using HP Ni sepharose column chromatography. Recombinant MAT2A homodimer was eluted with 250 and 500 mM imidazole, and fractions containing MAT2A were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis and pooled.
  • protein was diluted to 4 pg/mL in assay buffer (50 mM Tris, pH 8.0, 50 mM KC1, 15 mM MgCh, 0.3 mM EDTA, 0.005% [w/v] bovine serum albumin [BSA]).
  • Test compound was prepared in 100% dimethyl sulfoxide (DMSO) at 50* the desired final concentration.
  • DMSO dimethyl sulfoxide
  • a 1 pL volume of compound dilution was added to 40 pL of enzyme dilution and the mixture was allowed to equilibrate for 60 minutes at 25 °C.
  • the enzymatic assay was initiated by the addition of 10 pL of substrate mix (500 pM ATP, pH 7.0, 400 pM L- methionine in 1 x assay buffer), and the mixture was incubated for a further 60 minutes at 25 °C. The reaction was halted and the liberated phosphate released by the enzyme in stoichiometric amounts by the production of S-adenosyl methionine (SAM) was measured using the PiColorLock Gold kit (Innova Biosciences, UK). Absolute product amounts were determined by comparison to a standard curve of potassium phosphate buffer, pH 8.0.
  • substrate mix 500 pM ATP, pH 7.0, 400 pM L- methionine in 1 x assay buffer
  • SAM S-adenosyl methionine
  • Measurement of MAT2A activity in cells was made by direct quantitation of the abundance of the product of its enzymatic activity, SAM. Cancer cells were treated with candidate MAT2A inhibitors for a suitable incubation period, and the cells were then lysed using a reagent which quenched any further enzyme activity. Soluble metabolites including SAM were collected and SAM itself was directly measured from the lysate using quantitative LC-MS/MS.
  • a typical assay was performed using an HCT116 human colon carcinoma cell line which was genetically engineered to delete the MTAP gene (commercially available from Horizon Discovery). This cell line was utilized because it was determined that loss of the MTAP gene predicts sensitivity to MAT2A inhibitors.
  • Cells were plated in 96-well dishes at appropriate cell density. Following 24 hours, cells were then treated with the candidate MAT2A inhibitor. Prior to addition to cells, the compound was first serially diluted in 100% DMSO, typically as a 3-fold serial dilution starting at 500x top dose with 10 dose points including DMSO only control. Compound was then transferred to a working stock plate in cell culture media by adding 5 pL of compound in DMSO to 495 pL of cell culture media.
  • This working stock was then added to cells via a further 5-fold dilution, by adding 25 pL of working stock to 100 pL of cells in culture media. Following compound addition, cells were incubated at 37 °C / 5% CO2 for 72 hrs.
  • LC-MS/MS analysis was performed using an API6500 Mass Spectrometer (Sciex, Framingham, MA, USA) operating in positive ion spray mode and equipped with a Waters UPLC Acquity (Waters, Milford, MA, USA) BEH Amide column. Multiple Reaction Monitoring data was acquired for SAM and the d3-SAM standard, using a mass transition pair at m/z 399.2 250.1 and 402.2 250.1, respectively.
  • the initial flow rate was 0.5 ml/min of 25% mobile phase A (acetonitrile and water at 5:95 (v/v) with 1% formic acid and 10 mM ammonium acetate) and 75% mobile phase B
  • Test compound impact on cancer cell growth was assessed by treating cancer cells with compound for 4 days and then measuring proliferation using an ATP-based cell proliferation readout (Cell Titer Glo, Promega Corporation).
  • HCT116 human colon carcinoma cell lines which vary only in MTAP deletion status (HCT116 MTAP+/+ and HCT116 MTAP-/-) were plated in 96-well dishes at appropriate cell density. Following 24 hours, cells were then treated with the candidate MAT2A inhibitor. Prior to addition to cells, the compound was first serially diluted in 100% DMSO, typically as a 3-fold serial dilution starting at 500* top dose with 10 dose points including DMSO only control. Compound was then transferred to a working stock plate in cell culture media by adding 5 pL of compound in DMSO to 495 pL of cell culture media. This working stock was then added to cells via a further 5-fold dilution, by adding 25 pL of working stock to 100 pL of cells in culture media. Following compound addition, cells were incubated at 37 °C / 5% C02 for 4 days.
  • Luminescent signal was then measured using a plate-based luminometer Veritas version 1.9.2 using ATP standard curve to confirm assay reproducibility from run to run. This luminescence measure was converted to a proliferation index by subtracting from each data point the ATP luminescence signal measured from a bank (no cells) well and dividing by the ATP luminescence signal measured in 0.2% DMSO control well adjusted for signal in blank well. Compound activity was then represented as a percentage change in proliferation relative to a within-plate DMSO control against loglO of compound concentration in molar (M) units.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2019/068652 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer WO2020139991A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
RS20230240A RS64135B1 (sr) 2018-12-27 2019-12-27 Aza-heterobicklični inhibitori mat2a i metode upotrebe za lečenje raka
MA54608A MA54608B1 (fr) 2018-12-27 2019-12-27 Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
FIEP19845796.2T FI3902803T3 (fi) 2018-12-27 2019-12-27 Atsaheterobisyklisiä mat2a:n inhibiittoreita ja käyttömenetelmiä syövän hoitamiseksi
JP2021538127A JP7418441B2 (ja) 2018-12-27 2019-12-27 Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法
LTEPPCT/US2019/068652T LT3902803T (lt) 2018-12-27 2019-12-27 Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
CA3124952A CA3124952A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2021007829A MX2021007829A (es) 2018-12-27 2019-12-27 Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer.
EA202191801A EA202191801A1 (ru) 2018-12-27 2019-12-27 Гетероциклические ингибиторы mat2a и способы применения для лечения рака
AU2019416349A AU2019416349B2 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
SI201930515T SI3902803T1 (sl) 2018-12-27 2019-12-27 Aza-heterobiciklični inhibitorji mat2a in postopki uporabe za zdravljenje raka
BR112021012595-7A BR112021012595A2 (pt) 2018-12-27 2019-12-27 Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
IL284326A IL284326B1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
KR1020217023828A KR20220051301A (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
PE2021001086A PE20212090A1 (es) 2018-12-27 2019-12-27 Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer
MDE20211082T MD3902803T2 (ro) 2018-12-27 2019-12-27 Inhibitori aza-heterobiciclici ai MAT2A și metode de utilizare pentru tratarea cancerului
US17/418,442 US20220144820A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
UAA202104321A UA127525C2 (uk) 2018-12-27 2019-12-27 Гетероциклічні інгібітори mat2a і способи застосування для лікування раку
SG11202106637SA SG11202106637SA (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JOP/2021/0172A JOP20210172A1 (ar) 2018-12-27 2019-12-27 مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
CN201980092742.2A CN113454085B (zh) 2018-12-27 2019-12-27 Mat2a的aza杂双环抑制剂和用于治疗癌症的方法
DK19845796.2T DK3902803T3 (da) 2018-12-27 2019-12-27 Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
ES19845796T ES2942310T3 (es) 2018-12-27 2019-12-27 Inhibidores aza-heterobicíclicos de MAT2A y métodos de uso para el tratamiento del cáncer
PL19845796.2T PL3902803T3 (pl) 2018-12-27 2019-12-27 Aza-heterobicykliczne inhibitory mat2a i sposoby zastosowania do leczenia nowotworu
EP19845796.2A EP3902803B1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20210410A CR20210410A (es) 2018-12-27 2019-12-27 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
ZA2021/04423A ZA202104423B (en) 2018-12-27 2021-06-25 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CONC2021/0009879A CO2021009879A2 (es) 2018-12-27 2021-07-27 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
JP2023208546A JP2024015340A (ja) 2018-12-27 2023-12-11 Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785519P 2018-12-27 2018-12-27
US62/785,519 2018-12-27

Publications (1)

Publication Number Publication Date
WO2020139991A1 true WO2020139991A1 (en) 2020-07-02

Family

ID=69400625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/068652 WO2020139991A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Country Status (35)

Country Link
US (1) US20220144820A1 (hr)
EP (1) EP3902803B1 (hr)
JP (2) JP7418441B2 (hr)
KR (1) KR20220051301A (hr)
CN (1) CN113454085B (hr)
AR (1) AR117544A1 (hr)
AU (1) AU2019416349B2 (hr)
BR (1) BR112021012595A2 (hr)
CA (1) CA3124952A1 (hr)
CL (1) CL2021001721A1 (hr)
CO (1) CO2021009879A2 (hr)
CR (1) CR20210410A (hr)
DK (1) DK3902803T3 (hr)
EA (1) EA202191801A1 (hr)
ES (1) ES2942310T3 (hr)
FI (1) FI3902803T3 (hr)
GE (1) GEP20237519B (hr)
HR (1) HRP20230161T1 (hr)
HU (1) HUE061834T2 (hr)
IL (1) IL284326B1 (hr)
JO (1) JOP20210172A1 (hr)
LT (1) LT3902803T (hr)
MA (1) MA54608B1 (hr)
MD (1) MD3902803T2 (hr)
MX (1) MX2021007829A (hr)
PE (1) PE20212090A1 (hr)
PL (1) PL3902803T3 (hr)
PT (1) PT3902803T (hr)
RS (1) RS64135B1 (hr)
SG (1) SG11202106637SA (hr)
SI (1) SI3902803T1 (hr)
TW (1) TWI816962B (hr)
UA (1) UA127525C2 (hr)
WO (1) WO2020139991A1 (hr)
ZA (1) ZA202104423B (hr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046691B1 (en) 2018-12-10 2021-06-29 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
WO2022026892A1 (en) * 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022253242A1 (zh) * 2021-06-02 2022-12-08 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
WO2023114507A1 (en) * 2021-12-17 2023-06-22 Tango Therapeutics, Inc. Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof
US11986471B2 (en) 2018-07-18 2024-05-21 Tango Therapeutics, Inc. Compounds and methods of use
US11999713B2 (en) 2021-10-20 2024-06-04 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
KR20240051860A (ko) 2022-10-13 2024-04-22 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067634A1 (en) 1998-06-23 1999-12-29 The Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2018045071A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018215316A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2019191470A1 (en) * 2018-03-30 2019-10-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067634A1 (en) 1998-06-23 1999-12-29 The Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2018045071A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018215316A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2019191470A1 (en) * 2018-03-30 2019-10-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Lang's Handbook of Chemistry", 1985
"THE PRACTICE OF MEDICINAL CHEMISTRY", 1996, ACADEMIC PRESS, pages: 203
CAIRNS ET AL., NAT. GEN., vol. 11, 1995, pages 210 - 212
GARCIA-CASTELLANO ET AL., CLIN. CANCER RES., vol. 8, no. 3, 2002, pages 782 - 787
H. CHEN ET AL., GASTROENTEROLOGY, vol. 133, 2007, pages 207 - 218
J. CAI ET AL., CANCER RES., vol. 58, 1998, pages 1444 - 1450
K. MAIJON ET AL., CELL REPORTS, vol. 15, no. 3, 2016, pages 574 - 587
LU ET AL., CHEMISTRY & BIOLOGY, vol. 22, 2015, pages 755 - 763
M. FRAU ET AL., HEPATOLOGY, vol. 56, 2012, pages 165 - 75
M. FRAU ET AL., J. HEPATOL., vol. 59, 2013, pages 830 - 41
M. VAZQUEZ-CHANTADA ET AL., GASTROENTEROLOGY, vol. 138, 2010, pages 1943 - 53
POMERANTZ ET AL., CELL, vol. 92, 1998, pages 713 - 723
Q. LIU ET AL., HEPATOL. RES., vol. 37, 2007, pages 376 - 388
R. M. PASCALE ET AL., TRANSL. GASTROENTEROL. HEPATOL., vol. 3, 2018, pages 36
SYNLETT, vol. 23, 2012, pages 755 - 759
T. LI ET AL., J. CANCER, vol. 7, no. 10, 2016, pages 1317 - 1327
T. S. JANI ET AL., CELL. RES., vol. 19, 2009, pages 358 - 369
TETRAHEDRON, vol. 68, 2012, pages 3444 - 3449

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986471B2 (en) 2018-07-18 2024-05-21 Tango Therapeutics, Inc. Compounds and methods of use
US11046691B1 (en) 2018-12-10 2021-06-29 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US11084798B1 (en) 2018-12-10 2021-08-10 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US11130759B1 (en) 2018-12-10 2021-09-28 Ideaya Bioscience, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
WO2022026892A1 (en) * 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
US11492350B2 (en) 2020-07-31 2022-11-08 Tango Therapeutics, Inc. Compounds and methods of use
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022253242A1 (zh) * 2021-06-02 2022-12-08 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
US11999713B2 (en) 2021-10-20 2024-06-04 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof
WO2023114507A1 (en) * 2021-12-17 2023-06-22 Tango Therapeutics, Inc. Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof
US11999727B2 (en) 2022-04-29 2024-06-04 Tango Therapeutics, Inc. Compounds and methods of use

Also Published As

Publication number Publication date
CR20210410A (es) 2021-12-08
HUE061834T2 (hu) 2023-08-28
JP2022516883A (ja) 2022-03-03
MD3902803T2 (ro) 2023-10-31
JP7418441B2 (ja) 2024-01-19
RS64135B1 (sr) 2023-05-31
IL284326B1 (en) 2024-04-01
DK3902803T3 (da) 2023-02-13
JOP20210172A1 (ar) 2023-01-30
HRP20230161T1 (hr) 2023-04-28
MA54608B1 (fr) 2023-02-28
PE20212090A1 (es) 2021-11-04
EP3902803A1 (en) 2021-11-03
BR112021012595A2 (pt) 2021-09-08
JP2024015340A (ja) 2024-02-01
CN113454085B (zh) 2024-05-07
FI3902803T3 (fi) 2023-04-25
US20220144820A1 (en) 2022-05-12
LT3902803T (lt) 2023-04-25
MA54608A (fr) 2022-04-06
TW202039490A (zh) 2020-11-01
ES2942310T3 (es) 2023-05-31
AU2019416349B2 (en) 2023-09-28
UA127525C2 (uk) 2023-09-20
EP3902803B1 (en) 2023-02-01
GEP20237519B (en) 2023-07-10
SI3902803T1 (sl) 2023-06-30
AU2019416349A1 (en) 2021-07-15
PL3902803T3 (pl) 2023-05-22
CN113454085A (zh) 2021-09-28
EA202191801A1 (ru) 2021-11-09
KR20220051301A (ko) 2022-04-26
PT3902803T (pt) 2023-04-28
AR117544A1 (es) 2021-08-11
CO2021009879A2 (es) 2021-10-29
CA3124952A1 (en) 2020-07-02
IL284326A (en) 2021-08-31
TWI816962B (zh) 2023-10-01
MX2021007829A (es) 2021-10-26
SG11202106637SA (en) 2021-07-29
ZA202104423B (en) 2023-12-20
CL2021001721A1 (es) 2022-02-18

Similar Documents

Publication Publication Date Title
AU2019416349B2 (en) Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
EP3774805B1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020243376A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020139992A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
RU2809987C2 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
OA20638A (en) Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer.
EA046111B1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19845796

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3124952

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021538127

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021012595

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019416349

Country of ref document: AU

Date of ref document: 20191227

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 15703

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2019845796

Country of ref document: EP

Effective date: 20210727

ENP Entry into the national phase

Ref document number: 112021012595

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210625

WWE Wipo information: entry into national phase

Ref document number: 521422405

Country of ref document: SA